Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy.
OBJECTIVE
To determine the risk factors of severe radiation pneumonitis (RP) after stereotactic body radiation therapy (SBRT) for primary or secondary lung tumors.


METHODS
From January 2003 to March 2009, SBRT was performed on 117 patients (32 patients before 2005 and 85 patients after 2006) with lung tumors (primary = 74 patients and metastatic/recurrent = 43 patients) in our institution. In the current study, the results on cases with severe RP (grades 4-5) were evaluated. Serum Krebs von den Lungen-6 (KL-6) and serum Surfactant protein-D (SP-D) were used to predict the incidence of RP. A shadow of interstitial pneumonitis (IP) on the CT image before performing SBRT was also used as an indicator for RP. Since 2006, patients have been prescreened for biological markers (KL-6 & SP-D) as well as checking for an IP-shadow in CT.


RESULTS
Grades 4-5 RP was observed in nine patients (7.7%) after SBRT and seven of these cases (6.0%) were grade 5 in our institution. A correlation was found between the incidence of RP and higher serum KL-6 & SP-D levels. IP-shadow in patient's CT was also found to correlate well with the severe RP. Severe RP was reduced from 18.8% before 2005 to 3.5% after 2006 (p = 0.042). There was no correlation between the dose volume histogram parameters and these severe RP patients.


CONCLUSIONS
Patients presenting with an IP shadow in the CT and a high value of the serum KL-6 & SP-D before SBRT treatment developed severe radiation pneumonitis at a high rate. The reduction of RP incidence in patients treated after 2006 may have been attributed to prescreening of the patients. Therefore, pre-screening before SBRT for an IP shadow in CT and serum KL-6 & SP-D is recommended in the management and treatment of patients with primary or secondary lung tumors.
Yamashita
Hideomi
H
Department of Radiology, University of Tokyo Hospital, Hongo, Bunkyo-ku, Tokyo, Japan. yamashitah-rad@h.u-tokyo.ac.jp
Kobayashi-Shibata
Shino
S
Terahara
Atsuro
A
Okuma
Kae
K
Haga
Akihiro
A
Wakui
Reiko
R
Ohtomo
Kuni
K
Nakagawa
Keiichi
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000378:metabolism*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000378:metabolism / Q000601:surgery; D037663:Pulmonary Surfactant-Associated Protein D / Q000378:metabolism*; D017564:Radiation Pneumonitis / Q000209:etiology / Q000517:prevention & control*; D016634:Radiosurgery / Q000009:adverse effects*; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; C060192:MUC1 protein, human; D018396:Mucin-1; D037663:Pulmonary Surfactant-Associated Protein D
J Thorac Oncol. 2006 Oct;1(8):802-9
17409963
Phys Med Biol. 2006 Nov 7;51(21):5409-17
17047260
Semin Oncol. 2005 Apr;32(2 Suppl 3):S42-54
16015535
J Clin Oncol. 2006 Oct 20;24(30):4833-9
17050868
Cancer Control. 2008 Apr;15(2):140-50
18376381
Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):99-109
7642437
Am J Respir Crit Care Med. 2002 Feb 1;165(3):378-81
11818324
Cancer. 2006 Mar 15;106(6):1347-52
16475150
Cancer. 2007 Jul 1;110(1):148-55
17516437
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):374-81
18029106
Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):449-57
10974461
J Clin Oncol. 2009 Apr 1;27(10):1579-84
19255320
Radiother Oncol. 2003 Feb;66(2):141-50
12648785
Radiother Oncol. 2009 Jun;91(3):307-13
19321217
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1041-6
11958900
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):666-70
11597807
Radiat Oncol. 2007 Jun 07;2:21
17553175
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):416-25
17363190